1.
Wingerchuk
DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International
consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Neurology. 2015 Jul 14;85(2):177-89.
2.
Chitnis
T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus
statement: Evaluation of new and existing therapeutics for pediatric multiple
sclerosis. Lancet Neurol. 2018 Nov;17(11):978-987.
3.
Banwell
B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wender P, et al. Incidence
of acquired demyelination of the CNS in Canadian children. Neurology. 2007 Sep
25;69(13):1294-300.
4.
Kessler
RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder:
Acute, preventive, and symptomatic. Ther Adv Neurol Disord. 2020 Jan
24;13:1756286419895900.
5.
Huppke P,
Huppke B, Ellenberger D, Stark W, Röbl M, Gärtner J. Clinical characterization
of pediatric multiple sclerosis after 10 years of follow-up. Neurology. 2021
Apr 27;96(17)\:e2194-e2206.
6.
Cree BAC,
Arnold DL, Chataway J, Chitnis T, Fox RJ, Hartung HP, et al. Secondary progressive
multiple sclerosis: New insights. Mult Scler. 2020 Jan;26(1):20-36.
7.
Fujihara
K, Greenberg B, Bennett JL. NMOSD: Overview and updates on management. Ann
Neurol. 2019 Sep;86(3):407-417.
8.
Greenberg
BM, Graves D, Remington G, Harder L, Pardo CA, Bennett JL, et al. Acute
treatment of CNS inflammatory demyelinating disease. JAMA Neurol. 2017 Mar
1;74(3):285-293.
9.
Belman
AL, Krupp LB, Olsen CS, Gorman MP, Tillema JM, Aaen G, et al. Characteristics
of children and adolescents with multiple sclerosis. Pediatr Neurol. 2019 Jan; 94:3-13.
10. Hauser SL, Bar-Or A, Comi G, Giovannoni G,
Hartung HP, Hemmer B, et al. Ofatumumab versus teriflunomide in multiple
sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.
11. Waldman AT, Gorman MP, Rensel M, et al.
Management of pediatric multiple sclerosis. Curr Treat Options Neurol.
2016;18(3):10.
12. Steinman L, Brück W, Stadelmann C, Zamvil SS,
Hemmer B. The role of BTK in multiple sclerosis: Results from tolebrutinib
trials. Lancet Neurol. 2022 Dec;21(12):1012-1024.
13. Montalban X, Arnold DL, Weber MS, Staikov I,
Piasecka-Stryczynska K, Willmer-Hulme AJ, et al. Efficacy and safety of
ublituximab in relapsing multiple sclerosis. N Engl J Med. 2022 Dec
29;387(26):2411-2421.